Management ChangeJul 1, 2026, 04:22 PM
Climb Bio Board Sees Director Resignation, New Appointment
AI Summary
Climb Bio, Inc. announced that Andrew Levin resigned from its Board of Directors, effective June 29, 2026. Concurrently, Breanna O’Reilly, Ph.D., was elected as a new member of the Board, also effective June 29, 2026. Dr. O'Reilly will receive compensation including an option to purchase 70,284 shares at $13.36 per share, vesting over three years, and an annual cash retainer of $40,000.
Key Highlights
- Andrew Levin resigned from Climb Bio's Board of Directors, effective June 29, 2026.
- Breanna O’Reilly, Ph.D., was elected to the Board, effective June 29, 2026.
- Dr. O'Reilly's term expires at the Company’s 2027 annual meeting of stockholders.
- Granted option to purchase 70,284 shares at an exercise price of $13.36 per share.
- Option vests in equal monthly installments over three years from June 29, 2026.
- Will receive an annual cash retainer of $40,000 for her service as a director.
Price Impact
More from CLYM